Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial invigoration of immune response, and relief of symptom burden, SBRT has not demonstrated any improvement in survival. Preclinical research has established that STAT3 inhibition given concurrently with SBRT and in the maintenance phase acts as a synergistic agent that enhances the pro-inflammatory effects of SBRT while reducing its undesired effects (including fibrosis and immunosuppression). This study exploits the window of opportunity post-chemotherapy to advance the hypothesis that the addition of STAT3 inhibition in combination with SBRT will be safe and will enhance 2-year progression-free survival.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony patologicznie rak trzustki, który nie da się całkowicie usunąć chirurgicznie lub jest zaawansowany lokalnie
- •Ukończona chemioterapia wstępna 1-3 tygodnie przed rozpoczęciem leczenia (dla pacjentów z rakiem niepodlegającym całkowitej resekcji)
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (skala ECOG ≤ 2)
- •Wystarczająca funkcja szpiku kostnego, wątroby i nerek
- •Zdolność połykania tabletek
- •Normy krzepnięcia krwi w normie lub kontrolowane leki przeciwkrzepliwe
- •Zgoda na skuteczną antykoncepcję przez czas badania i 30 dni po ostatniej dawce leku (dotyczy kobiet i mężczyzn)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
University of Colorado
Aurora, United States
Washington University School of Medicine
St Louis, United States
Trial contact
Sana Karam, M.D., Ph.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.